Key facts
- This page summarizes Jeff Chiprin's Form 4 filing for IRADIMED CORP (IRMD).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 13 Dec 2024, 16:00.
Jeff Chiprin - 11 Dec 2024 Form 4 Insider Report for IRADIMED CORP (IRMD)
- Reporting relationship
- Chief Commercial Officer
- Issuer ticker
- IRMD
- Reported as of
- 11 Dec 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 13 Dec 2024, 16:00:14 UTC
- Prior SEC filing
- 06 Dec 2024
- Next SEC filing
- 12 Dec 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jeff Chiprin
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jeff Chiprin filed Form 4 for IRADIMED CORP (IRMD) on 13 Dec 2024.
Change
- Previous filing in this sequence was filed on 06 Dec 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IRMD
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +2,990
- Change %
- Price
- $0.000000
- Shares after
- 2,990
- Date
- 11 Dec 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,990
- Exercise price
- Footnotes
- F1, F2
IRMD
transaction
Derivative
Performance-based Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +2,989
- Change %
- Price
- $0.000000
- Shares after
- 2,989
- Date
- 11 Dec 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,989
- Exercise price
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
Footnote F2
The reporting person received RSUs under Iradimed Corporation's 2023 Equity Incentive Plan. The RSUs vest in three equal annual installments beginning on December 11, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.
Footnote F3
The reporting person received performance-based restricted stock units ("PRSUs") under Iradimed Corporation's 2023 Equity Incentive Plan. PRSUs convert into common stock on a one-for-one basis. The PRSUs vest over a three-year performance period from December 12, 2024 through December 11, 2027 on the Company's total stockholder return compared to the NASDAQ US Small Cap Medical Equipment index.